Invention:
This invention is a peptide that blocks eNOS phosphorylation. These peptides are designed to target the T495 phosporylation site of eNOS to prevent the activation of eNOS that leads to superoxide production and overwhelming inflammation. The initial peptide has been shown to reduce NOS derived superoxide and cell barrier loss throughout trials.
Background:
Pulmonary hypertension and ventilation-induced acute lung injuries can be devastating conditions. Pulmonary hypertension is a type of high blood pressure, which affects the arteries in the lungs and the right side of the heart. These lung diseases cause obvious breathing problems and affect the quality of life of any person who has them. There has been a great deal of medical attention, research, and monetary support to address the problems caused by these diseases. Protein nitration has been shown to be an important driver of these inflammatory diseases.
Applications:
- Blocking eNOS phosphorylation
- Preventing the damage caused by diseases, including:
- Pulmonary hypertension
- Ventilation-induced acute lung injury
Advantages:
- Helping to prevent the onset of certain diseases, including their dangerous symptoms
